Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 213

1.

Nanotechnology solutions for mucosal immunization.

Chadwick S, Kriegel C, Amiji M.

Adv Drug Deliv Rev. 2010 Mar 18;62(4-5):394-407. doi: 10.1016/j.addr.2009.11.012. Epub 2009 Nov 18. Review.

PMID:
19931581
2.

Delivery strategies to enhance mucosal vaccination.

Chadwick S, Kriegel C, Amiji M.

Expert Opin Biol Ther. 2009 Apr;9(4):427-40. doi: 10.1517/14712590902849224 . Review.

PMID:
19344280
3.

Mucosal immunisation: adjuvants and delivery systems.

Moyle PM, McGeary RP, Blanchfield JT, Toth I.

Curr Drug Deliv. 2004 Oct;1(4):385-96. Review.

PMID:
16305400
4.

Nanocarriers for systemic and mucosal vaccine delivery.

Shahiwala A, Vyas TK, Amiji MM.

Recent Pat Drug Deliv Formul. 2007;1(1):1-9. Review.

PMID:
19075870
5.

Mucosal delivery of vaccine antigens and its advantages in pediatrics.

De Magistris MT.

Adv Drug Deliv Rev. 2006 Apr 20;58(1):52-67. Epub 2006 Mar 3. Review.

PMID:
16516335
6.

Delivery systems: a vaccine strategy for overcoming mucosal tolerance?

Mann JF, Acevedo R, Campo JD, PĂ©rez O, Ferro VA.

Expert Rev Vaccines. 2009 Jan;8(1):103-12. doi: 10.1586/14760584.8.1.103. Review.

PMID:
19093777
7.

Mucosal adjuvants and delivery systems for protein-, DNA- and RNA-based vaccines.

Vajdy M, Srivastava I, Polo J, Donnelly J, O'Hagan D, Singh M.

Immunol Cell Biol. 2004 Dec;82(6):617-27. Review.

8.

Stimulation of local antibody production: parenteral or mucosal vaccination?

Bouvet JP, Decroix N, Pamonsinlapatham P.

Trends Immunol. 2002 Apr;23(4):209-13. Review.

PMID:
11923116
9.

Nanotechnology in vaccine delivery.

Peek LJ, Middaugh CR, Berkland C.

Adv Drug Deliv Rev. 2008 May 22;60(8):915-28. doi: 10.1016/j.addr.2007.05.017. Epub 2008 Feb 7. Review.

PMID:
18325628
10.

Polymer nanotechnology based approaches in mucosal vaccine delivery: challenges and opportunities.

Sharma R, Agrawal U, Mody N, Vyas SP.

Biotechnol Adv. 2015 Jan-Feb;33(1):64-79. doi: 10.1016/j.biotechadv.2014.12.004. Epub 2014 Dec 12. Review.

PMID:
25499178
11.

Recent advances in mucosal vaccine development.

Chen H.

J Control Release. 2000 Jul 3;67(2-3):117-28. Review.

PMID:
10825547
12.

Ensuring vaccine safety in immunization programmes--a WHO perspective.

Jodar L, Duclos P, Milstien JB, Griffiths E, Aguado MT, Clements CJ.

Vaccine. 2001 Feb 8;19(13-14):1594-605.

PMID:
11166881
13.

Poly(anhydride) nanoparticles as adjuvants for mucosal vaccination.

Irache JM, Salman HH, Gomez S, Espuelas S, Gamazo C.

Front Biosci (Schol Ed). 2010 Jun 1;2:876-90. Review.

PMID:
20515831
14.

[Development of antituberculous drugs: current status and future prospects].

Tomioka H, Namba K.

Kekkaku. 2006 Dec;81(12):753-74. Review. Japanese.

PMID:
17240921
15.
16.

Mucosal adjuvants.

Harandi AM, Medaglini D.

Curr HIV Res. 2010 Jun;8(4):330-5. Review.

PMID:
20353395
17.

Mucosal immunization: a realistic alternative.

Otczyk DC, Cripps AW.

Hum Vaccin. 2010 Dec;6(12):978-1006. Epub 2010 Dec 1. Review.

PMID:
21150284
18.

Implication of nanoparticles/microparticles in mucosal vaccine delivery.

Vyas SP, Gupta PN.

Expert Rev Vaccines. 2007 Jun;6(3):401-18. Review.

PMID:
17542755
19.

New insights in mucosal vaccine development.

Pavot V, Rochereau N, Genin C, Verrier B, Paul S.

Vaccine. 2012 Jan 5;30(2):142-54. doi: 10.1016/j.vaccine.2011.11.003. Epub 2011 Nov 12. Review.

PMID:
22085556
20.

Jump-starting the immune system: prime-boosting comes of age.

Woodland DL.

Trends Immunol. 2004 Feb;25(2):98-104. Review.

PMID:
15102369

Supplemental Content

Support Center